|
|
|
| First Name: | Richard C. | | Last Name: | Mohs | | Title: | Leader, Alzheimer's Disease Team | | Advanced Degrees: | Ph.D. | | Affiliation: | Eli Lilly and Company | | Department: | Global Brand Development | | Street Address 1: | Lilly Corporate Center | | Street Address 2: | Drop Code: 6161 | | City: | Indianapolis | | State/Province: | IN | | Zip/Postal Code: | 46285 | Country/Territory: | U.S.A. | | Phone: | 317 651-8324 | | Fax: | 317 277-6286 | | Email Address: |  |
Disclosure:
(view policy)
|
Member reports the following financial or other potential conflicts of interest: [Last Modified: 20 January 2009]
I am an employee of Eli Lilly and Co.
|
|
|
View all comments by Richard C. Mohs
|
Aging Process, Alzheimer Disease, Neurodevelopmental Disorders (Down syndrome, etc.), Stroke and Trauma
|
A-beta PP/A-beta, Drug screening, Diagnosis, Brain imaging, Clinical trials
|
Richard C. Mohs, Ph.D. is a Distinguished Research Fellow in the Neuroscience Therapeutic Area at Eli Lilly and Company; he also holds faculty appointments at the Indiana University School of Medicine and the Mount Sinai School of Medicine in New York. Before joining Eli Lilly in 2002 Dr. Mohs spent 23 years with the Mount Sinai School of Medicine where he was Professor in the Department of Psychiatry and also served as Associate Chief of Staff for Research at the Bronx Veterans Affairs Medical Center. Dr. Mohs received his doctoral degree in psychology from Stanford University and completed fellowship training in psychopharmacology at the Stanford University School of Medicine. The author or co-author of over 300 scientific papers Dr. Mohs has conducted numerous research studies on aging, Alzheimer’s disease, schizophrenia and cognitive function. He was the principal developer of the Alzheimer’s Disease Assessment Scale (ADAS), an instrument used worldwide to evaluate drug treatments for dementia, and he was a lead investigator for clinical trials that led to the approval, in the U.S. and other countries, of cholinergic drug treatments for Alzheimer’s disease. With collaborators at Mount Sinai, Dr. Mohs helped determine the clinical and neuropathologic changes occuring at the very earliest stages of Alzheimer’s disease. He also helped map the lifetime course of cognitive deficits in schizophrenia and developed tools to assess treatments for these cognitive deficits. Dr. Mohs has served as an advisor to many neuroscience research programs at medical schools throughout the United States and to several foundations supporting neuroscience research including the John D. and Catherine T. MacArthur Foundation, the Charles A. Dana Foundation, the Institute for the Study of Aging and the Fisher Center for Alzheimer’s Research Foundation.
|
1)Rosen, WG, Mohs, RC, Davis, KL. A new rating scale for Alzheimer's disease. American Journal of Psychiatry, 1984, 141:1356-1364.
2)Mohs, RC, Davis, BM, Johns, CA, Mathe, AA, Greenwald, BS, Horvath, TB, Davis, KL. Oral physostigmine treatment of patients with Alzheimer's disease. American Journal of Psychiatry, 1985, 142:28-33.
3)Mohs, RC, Breitner, JCS, Silverman, JM, Davis, KL. Alzheimer's disease: morbid risk among first degree relatives approximates 50% by age 90. Archives of General Psychiatry, 1987, 44:405-408.
4)Morris, JC, Heyman, A, Mohs, RC, Hughes, J, Van Belle, G, Fillenbaum, G, Mellits, ED, Clark, C. and the CERAD investigators. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology, 1989, 39:1159-1165.
5)Berkman, LF, Seeman, TE, Albert, M, Blazer, D, Kahn, R, Mohs, R, Finch, C, Schneider, E, Cotman, C, McClearn, G, Nesselroade, J, Featherman, D, Garmezy, N, McKhann, G, Brim, G, Prager, D, Rowe, J. High, usual and impaired functioning in community-dwelling older men and women: Findings from the MacArthur Foundation Research Network on Successful Aging. Journal of Clinical Epidemiology, 1993, 46:1129-1140.
6)Davidson, M, Harvey, PD, Welsh, KA, Powchik, P, Putnam, KM, Mohs, RC. Cognitive functioning in late-life schizophrenia: A comparison of elderly schizophrenic patients and patients with Alzheimer's disease. American Journal of Psychiatry, 1996, 153:1274-1279.
7)Hazlett, EA, Buchsbaum, MS, Mohs, RC, Spiegel-Cohen, J, Wei, T-C, Azueta, R, Haznedar, MM, Singer, MB, Shihabuddin, L, Luu-Hsia, C, Harvey, PD. Age-related shift in brain region activity during successful memory performance. Neurobiology of Aging, 1998, 19:437-445.
8)Naslund, J, Haroutunian, V, Mohs, R, Davis, KL, Davies, P, Greengard, P, Buxbaum, JD. Elevated amyloid b-peptides in brain: correlation with cognitive decline. Journal of the American Medical Association, 2000, 283:1571-1577.
9)Mohs, RC, Doody, RS, Morris, JC, Ieni, JR, Rogers, SL, Perdomo, CA, Pratt, RD for the "312" Study Group. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1-year prospective, placebo-controlled functional survival study. Neurology, 2001, 57:481-488.
10)Silverman, JM, Smith, CJ, Marin, DB, Mohs, RC, Propper, CB. Familial patterns of risk in very late-onset Alzheimer's disease. Archives of General Psychiatry, 2003, 60:190-197. |
We do not understand the relationships among the neuropathological features of AD, namely beta-amyloid, tangles, cellular dysfunction and cellular loss. |
AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomized double-blind trial. Lancet, 2004, 363:2105-2115.
Shumaker, SA, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. Journal of the American Medical Association, 2003, 289:2651-2662.
|
Test the effects of several novel compounds on symptoms and biomarkers of Alzheimer's disease. |
Compounds affecting the amount of free beta protein in brain will have both symptomatic and disease modifying effects in AD. |
Pharmacological modulation of APOE will affect the onset of AD. |
|
|
Home
